# A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer

> **NCT01710592** · PHASE2 · COMPLETED · sponsor: **Cancer Trials Ireland** · enrollment: 35 (actual)

## Conditions studied

- Gastro Oesophageal Cancer

## Interventions

- **DRUG:** Epirubicin
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01710592
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2012-12
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01710592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01710592, "A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01710592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*